AVITA Medical Successfully Completes Australian Equity Raise
AVITA Medical (NASDAQ: RCEL) has successfully completed a private placement in Australia, raising approximately US$15 million (A$23 million) through the issuance of 17.2 million new CHESS Depositary Interests (CDIs). The placement was priced at A$1.32 per CDI, representing an 11% discount to the last closing price of A$1.48.
The funds will be utilized for working capital requirements and strategic flexibility to support the company's therapeutic acute wound portfolio growth. AVITA Medical expects this capital to sustain operations until it achieves free cash flow in 2026. The new CDIs are scheduled for settlement on August 19, 2025, with trading on the ASX commencing August 20, 2025.
AVITA Medical (NASDAQ: RCEL) ha completato con successo un collocamento privato in Australia, raccogliendo circa US$15 milioni (A$23 milioni) mediante l'emissione di 17,2 milioni di nuovi CHESS Depositary Interests (CDI). Il collocamento è stato effettuato a A$1,32 per CDI, corrispondente a uno sconto dell'11% rispetto al prezzo di chiusura precedente di A$1,48.
I fondi saranno impiegati per il fabbisogno di capitale circolante e per garantire flessibilità strategica a sostegno della crescita del portafoglio terapeutico per ferite acute. AVITA Medical prevede che questo capitale sosterrà le operazioni fino al raggiungimento del free cash flow nel 2026. I nuovi CDI sono previsti in regolamento il 19 agosto 2025, con inizio delle negoziazioni su ASX il 20 agosto 2025.
AVITA Medical (NASDAQ: RCEL) ha cerrado con éxito una colocación privada en Australia, recaudando aproximadamente US$15 millones (A$23 millones) mediante la emisión de 17,2 millones de nuevos CHESS Depositary Interests (CDI). La colocación se fijó en A$1,32 por CDI, lo que supone un descuento del 11% respecto al último precio de cierre de A$1,48.
Los fondos se utilizarán para necesidades de capital de trabajo y para mantener flexibilidad estratégica que respalde el crecimiento de la cartera terapéutica para heridas agudas. AVITA Medical espera que este capital sostenga las operaciones hasta alcanzar flujo de caja libre en 2026. Los nuevos CDI se liquidarán el 19 de agosto de 2025 y comenzarán a cotizar en la ASX el 20 de agosto de 2025.
AVITA Medical (NASDAQ: RCEL)이 호주에서 사모 유상증자를 성공적으로 완료하여 약 미화 1,500만 달러(A$2,300만)를 1,720만 주의 신규 CHESS 예탁증서(CDI) 발행으로 조달했습니다. 배정 단가는 CDI당 A$1.32로, 직전 종가 A$1.48에 비해 11% 할인된 수준입니다.
조달 자금은 운전자본 수요와 급성 상처 치료 포트폴리오의 성장 지원을 위한 전략적 유연성 확보에 사용될 예정입니다. AVITA Medical은 이 자금으로 2026년에 자유현금흐름을 달성할 때까지 운영을 유지할 것으로 예상합니다. 신규 CDI는 2025년 8월 19일 결제될 예정이며, 2025년 8월 20일부터 ASX에서 거래가 시작됩니다.
AVITA Medical (NASDAQ: RCEL) a réussi un placement privé en Australie, levant environ 15 M$ US (23 M$ A) via l'émission de 17,2 millions de nouveaux CHESS Depositary Interests (CDI). Le placement a été réalisé à A$1,32 par CDI, soit une décote de 11% par rapport au dernier cours de clôture de A$1,48.
Les fonds seront utilisés pour les besoins en fonds de roulement et pour offrir une flexibilité stratégique afin de soutenir la croissance du portefeuille thérapeutique pour les plaies aiguës. AVITA Medical s'attend à ce que ce capital permette de financer les opérations jusqu'à l'obtention d'un flux de trésorerie disponible en 2026. Les nouveaux CDI devraient être réglés le 19 août 2025, avec une cotation sur l'ASX à partir du 20 août 2025.
AVITA Medical (NASDAQ: RCEL) hat eine Privatplatzierung in Australien erfolgreich abgeschlossen und dabei rund US$15 Millionen (A$23 Millionen) durch die Ausgabe von 17,2 Millionen neuen CHESS Depositary Interests (CDIs) aufgenommen. Der Platzierungspreis lag bei A$1,32 pro CDI, was einem Abschlag von 11% zum letzten Schlusskurs von A$1,48 entspricht.
Die Mittel werden für den Betriebsfinanzierungsbedarf und zur Schaffung strategischer Flexibilität zur Unterstützung des Wachstums des therapeutischen Portfolios für akute Wunden verwendet. AVITA Medical geht davon aus, dass dieses Kapital den Betrieb bis zur Erzielung eines freien Cashflows im Jahr 2026 unterstützen wird. Die neuen CDIs werden voraussichtlich am 19. August 2025 abgewickelt, mit Handelsbeginn an der ASX am 20. August 2025.
- None.
- 11% discount to market price indicates dilution for existing shareholders
- Additional equity raise suggests current cash position needs reinforcement
Insights
AVITA raised $15M through Australian private placement, extending runway until projected 2026 free cash flow begins.
AVITA Medical has successfully raised
The structure of this raise is telling—by tapping Australian investors rather than U.S. markets despite dual-listing status, AVITA likely found more favorable reception among ASX investors for this financing round. The
Most significantly, this announcement provides clear visibility into AVITA's financial runway. Management's explicit statement that this funding will cover operations until free cash flow begins in 2026 offers a concrete timeline for reaching operational self-sufficiency. For a therapeutic company, projecting positive free cash flow within approximately 18 months signals confidence in accelerating commercialization of their acute wound care portfolio.
New investors should note these shares will be fully tradable by August 20th and will rank equally with existing shares, avoiding any preferential treatment for the placement participants beyond the initial discount.
- Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX)
- Issue price of A
$1.32 per New CDI, raising approximately US$15 million (~A$23 million ), with participation from new and existing Australian shareholders
VALENCIA, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the successful completion of a private placement (the “Placement”) to institutional and professional investors in Australia to raise an approximate gross amount of US
Proceeds from the Placement will be used for working capital requirements and will provide additional strategic flexibility to support continued growth of the Company’s therapeutic acute wound portfolio. This is expected to cover operations until free cash flow begins in 2026.
“The strong support we received in this Placement reflects growing confidence in our strategy and the transformative potential of our therapeutic acute wound care portfolio,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “We welcome our new Australian shareholders and extend our sincere gratitude to our existing investors for their continued support.”
MST Financial Services Pty Limited acted as sole lead manager.
Placement Details
The Company will issue approximately 17.2 million New CDIs under the Placement at the Offer Price of A
The New CDIs are being issued by the Company in accordance with the Company’s available placement capacity pursuant to ASX Listing Rule 7.1.
The New CDIs are expected to be settled on August 19, 2025, and to be allotted and to commence trading on the ASX shortly thereafter on August 20, 2025. New CDIs issued under the Placement will rank equally with the Company’s existing CDIs on issue.
Indicative Timetable*
| Event | Date |
| Launch of Offer | Tuesday, August 12, 2025 |
| Announcement of completion of Placement | Wednesday, August 13, 2025 |
| Settlement of New CDIs under the Placement | Tuesday, August 19, 2025 |
| Allotment, quotation and trading of New CDIs under the Placement | Wednesday, August 20, 2025 |
*The above timetable reflects the Australian time zone and the dates may change. AVITA Medical reserves the right to amend these dates at its absolute discretion, subject to the Corporations Act (2001) (Cth), the ASX Listing Rules, and other applicable laws. The quotation of the New CDIs is subject to confirmation from the ASX.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Notice to U.S. persons: restriction on purchasing CDIs
AVITA Medical is incorporated in the State of Delaware and its CDIs have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the laws of any state or other jurisdiction in the United States. Trading of AVITA Medical’s CDIs on the Australian Securities Exchange (the “ASX”) is not subject to the registration requirements of the Securities Act in reliance on Regulation S under the Securities Act, as supplemented by a related “no action” letter issued by the U.S. Securities and Exchange Commission (the “SEC”) to the ASX in 2000. As a result, the CDIs are “restricted securities” (as defined in Rule 144 under the Securities Act) and may not be sold or otherwise transferred except in transactions exempt from, or not subject to, the registration requirements of the Securities Act. To enforce the transfer restrictions, the CDIs will bear a FOR Financial Product designation on the ASX. This designation restricts CDIs from being purchased by U.S. persons. Finally, any hedging transaction with regard to the CDIs may only be conducted in compliance with the Securities Act.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com
Authorized for release by the Board of Directors of AVITA Medical, Inc.
FAQ
How much did AVITA Medical (RCEL) raise in its Australian equity placement?
What is the purpose of AVITA Medical's 2025 capital raise?
When will the new AVITA Medical CDIs begin trading on the ASX?
What was the pricing of AVITA Medical's 2025 private placement?
When does AVITA Medical expect to achieve free cash flow?
